Bayer’s Three-Way Test: A Supreme Court Ruling, a Settlement Hearing, and a Trade War Threat
Published on 06/19/2026 at 12:15 | Redaktion boerse-global.de
Bayer investors are caught in a tug-of-war between two vastly different signals from across the Atlantic — and a ticking clock in Washington, D.C. While the European Parliament just handed the German conglomerate a long-term gift for its seeds business, the U.S. government has launched an investigation into its pharmaceutical pricing that could culminate in punitive tariffs. All of this unfolds with a Supreme Court decision due in less than two weeks that may determine the fate of thousands of glyphosate lawsuits.
The most consequential date on the calendar is 22 June, when the Supreme Court is expected to rule in the Durnell case. The central question is whether state-level warning requirements can override the federal authority of the Environmental Protection Agency on glyphosate labelling. Analysts put the odds of a favourable outcome for Bayer at roughly 60 percent. Should the court side with the company, a large chunk of the remaining Roundup litigation could collapse — opening the door to a significant re-rating of the stock, which currently trades 26 percent below its 52-week high of €49.93.
That re-rating is far from guaranteed, but the market is already pricing in a degree of risk. The annualised 30-day volatility stands at 33 percent, underscoring the binary nature of the bet. The stock changed hands at €36.98 on Friday, a marginal daily decline but still just above its 200-day moving average of €36.22. Over 12 months the shares have advanced roughly 38 percent, though they are slightly in the red year to date.
Should investors sell immediately? Or is it worth buying Bayer?
Brussels provided a quieter but strategically important boost on 17 June, when the European Parliament approved a compromise that loosens the rules on New Genomic Techniques (NGT). Under the new framework, plants developed through these methods can be patented, and NGT-1 varieties will no longer require special labelling for food or animal feed. The regulation is set to take effect by mid-2028. For Bayer’s Crop Science division, this is a clear shot in the arm, giving it more leeway to innovate and secure intellectual property — even if the financial impact will take years to materialise.
That tailwind was offset by a fresh headwind from Washington on Friday. U.S. Trade Representative Jamieson Greer opened a formal investigation into German pharmaceutical pricing practices, accusing Berlin of keeping drug prices artificially low while American patients shoulder a disproportionate share of research costs. If the probe finds evidence of unfair trade practices, the U.S. could impose tariffs on imported medicines — directly threatening Bayer’s pharma segment, which had been seen as a stabilising force amid the legal turmoil. Months of talks between Washington and Berlin have yielded no agreement; the U.S. struck a similar deal with Britain in April.
On the litigation front, the company secured a tactical win when a U.S. judge sent the multibillion-dollar glyphosate class-action settlement — originally valued at $7.25 billion — back to a Missouri state court. That gives Bayer greater procedural control. The next hearing on the settlement’s approval is scheduled for 9 July 2026 in St. Louis. Meanwhile, Goldman Sachs trimmed its voting stake in Bayer to 4.84 percent as of 15 June, down from 5.40 percent three days earlier — a modest reduction but another sign that institutional positioning is being re-evaluated.
Analysts remain cautiously optimistic. UBS’s Matthew Weston reiterated a “Buy” rating with a €52.00 target, citing the legal progress in Missouri. Berenberg maintains a “Hold” at €40.50, while Jefferies is also on “Hold” at €40.00. The broad consensus is that the stock’s risk-reward profile is improving, but only for those willing to stake a claim on the Supreme Court outcome. With the 52-week low from August 2025 sitting nearly 47 percent below the current price, a favourable ruling could unlock substantial upside. A defeat, however, would leave Bayer’s legal overhang very much intact — and the new trade investigation adds a layer of uncertainty that was not there a week ago.
Ad
Bayer Stock: New Analysis - 19 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
